



Continuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions

Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. *J Hypertens*. 1994;12:609-615.

Aresta C, Soranna D, Giovanelli L, et al. When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. *Endocr Pract*. 2021;27(12):1216-1224.

Bhatt DL, Taub P, Laffin L, et al. Prevalence And Clinical Impact Of Hypercortisolism In Individuals With Resistant Hypertension: Primary Results From The Momentum Study. Presented at American College of Cardiology's Annual Scientific Session (ACC.26). March 27-30, 2026. New Orleans, LA. Available at: ACC 75th Annual Scientific Sessions - Prevalence And Clinical Impact Of Hypercortisolism In Individuals With Resistant Hypertension: Primary Results From The Momentum Study. Accessed April 1, 2026.

Braun LT, Vogel F, Nowak E, et al. Frequency of clinical signs in patients with Cushing's syndrome and mild autonomous cortisol secretion: overlap is common. *Eur J Endocrinol*. 2024;191(4):473-479.

Braun LT, Riester A, Oßwald-Kopp A, et al. Toward a Diagnostic Score in Cushing's Syndrome. *Front Endocrinol (Lausanne)*. 2019;10:766.

Buse JB, Kahn SE, Aroda VR, et al; CATALYST Investigators*. Prevalence of hypercortisolism in difficult-to-control type 2 diabetes. *Diabetes Care*. 2025;48(12):2012-2020.

Ceccato F, Terzolo M, Gatto F, et al. Who and how to screen for Cushing's syndrome: the position statement of the Italian Society of Endocrinology. *J Endocrinol Invest*. 2025 Dec 9. doi: 10.1007/s40618-025-02758-3. Epub ahead of print. PMID: 41364328.

Chiodini I, Vainicher CE, Morelli V, et al. MECHANISMS IN ENDOCRINOLOGY: Endogenous subclinical hypercortisolism and bone: a clinical review. *Eur J Endocrinol*. 2016;175(6):R265-R282.

ClinicalTrials.gov. Osilodrostat in Patients With Hypertension Caused by Hypercortisolemia Due to Cushing's Syndrome (LINC CARE). Available at: <https://clinicaltrials.gov/study/NCT07247162?cond=hypercortisolism%20hypertension&rank=2>. Accessed February 4, 2026.

DeFronzo RA, Fonseca V, Aroda VR, et al, CATALYST Investigators*; Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. *Diabetes Care*. 2025;48(12):2036-2044.

Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. *Eur J Endocrinol*. 2012;166(4):669-77.

Fallo F, Di Dalmazi G, Beuschlein F, et al. Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. *J Hypertens*. 2022;40(11):2085-2101.

Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. *Eur J Endocrinol*. 2023;189(1):G1-G42.

Fleseriu M, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. *Lancet Diabetes Endocrinol*. 2021;9:847-875.



Continuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions

Giovanelli L, Aresta C, Favero V, et al. Hidden hypercortisolism: a too frequently neglected clinical condition. *J Endocrinol Invest.* 2021;44(8):1581-1596.

Jusufović S, Halilčević A, Jusufović R, et al. The Prevalence of Hypercortisolism in Patients with Type 2 Diabetes and Microvascular Complications: A Prospective Observational Case-Control Study. *Clinical Diabetology.* 2024;13(5):246–253.

Khawandanah D, ElAsmar N, Arafah BM. Alterations in hypothalamic-pituitary-adrenal function immediately after resection of adrenal adenomas in patients with Cushing's syndrome and others with incidentalomas and subclinical hypercortisolism. *Endocrine.* 2019;63(1):140-148.

Martins LC, Conceição FL, Muxfeldt ES, Salles GF. Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension. *J Hypertens.* 2012;30(5):967-73.

Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2008;93(5):1526-1540.

Nieman LK. Cushing's syndrome: update on signs, symptoms and biochemical screening. *Eur J Endocrinol.* 2015;173(4):M33-M38.

Omura M, Saito J, Yamaguchi K, et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. *Hypertens Res.* 2004;27(3):193-202.

Paschou SA, Kandarakis E, Dimitropoulou F, et al. Subclinical Cushing's syndrome in patients with bilateral compared to unilateral adrenal incidentalomas: a systematic review and meta-analysis. *Endocrine.* 2016;51(2):225-235.

Petramala L, Olmati F, Concistrè A, et al. Cardiovascular and metabolic risk factors in patients with subclinical Cushing. *Endocrine.* 2020;70(1):150-163.

Plutzky J, Taub PR, Bhatt DL, et al. Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design. *JACC Adv.* 2026;5(3):102596.

Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing's syndrome: state of the art. *Lancet Diabetes Endocrinol.* 2016;4(7):611-629.

Prete A, Subramanian A, Bancos I, et al; ENSAT EURINE-ACT Investigators*; ENSAT EURINE-ACT Investigators. Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors: A Cross-Sectional Multicenter Study. *Ann Intern Med.* 2022;175(3):325-334.

Pugliese F, Salcuni AS, Battista C, et al. Prevalence of less severe hypercortisolism in fractured patients admitted in an outpatient clinic for metabolic bone diseases. *Endocrine.* 2021;73(1):203-208.

Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes - 2026 Update. *Endocr Pract.* 2026:S1530-891X(26)00022-4.

Steffensen C, Dekkers OM, Lyhne J, et al. Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients. *Horm Metab Res.* 2019;51(1):62-68.

Steffensen C, Pereira AM, Dekkers OM, Jørgensen JO. DIAGNOSIS OF ENDOCRINE DISEASE: Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis. *Eur J Endocrinol.* 2016;175(6):R247-R253.



Continuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions

Trifanescu R, Carsote M, Caragheorgheopol A, et al. Screening for secondary endocrine hypertension in young patients. *Maedica (Bucur)*. 2013;8(2):108-15.

van Hulsteijn LT, Pasquali R, Casanueva F, et al. Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis. *Eur J Endocrinol*. 2020;182(1):11-21.

Wang L, Li N, Yao X, et al. Detection of Secondary Causes and Coexisting Diseases in Hypertensive Patients: OSA and PA Are the Common Causes Associated with Hypertension. *Biomed Res Int*. 2017;2017:8295010.